Fingolimod
- Generic Name
- Fingolimod
- Brand Names
- Gilenya, Tascenso, Fingolimod Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H33NO2
- CAS Number
- 162359-55-9
- Unique Ingredient Identifier
- 3QN8BYN5QF
- Background
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was a...
- Indication
Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- Alternative Treatment
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 4000
- Registration Number
- NCT06705608
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 194
- Registration Number
- NCT06408259
- Locations
- 🇷🇴
Local Institution - 0088, Bucharest, București, Romania
🇺🇸Local Institution - 0130, Sacramento, California, United States
🇺🇸UCSF Benioff Children's Hospital San Francisco, San Francisco, California, United States
Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06087965
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT05688436
- Locations
- 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
- Conditions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 30
- Registration Number
- NCT05423769
- Locations
- 🇪🇬
Neuropsychiatry department, Faculty of Medicine, Alexandria University Hospitals, Hadra University Hospital, Alexandria, Egypt
🇪🇬Faculty of medicine Ain shams Research Institute-Clinical Research Center (MASRI-CRC), Cairo, Egypt
Fingolimod for Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 40
- Registration Number
- NCT05307731
- Locations
- 🇨🇳
Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05285878
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Impact of Fingolimod Adherence on Outcomes
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 694
- Registration Number
- NCT05141669
- Locations
- 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT05123703
- Locations
- 🇺🇸
UC San Diego; ACTRI, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇷L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME, Brasilia, DF, Brazil
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT04926818
- Locations
- 🇺🇸
Childrens Healthcare Of Atlanta ., Atlanta, Georgia, United States
🇺🇸Arkansas Childrens Hosp Rsch Inst ., Little Rock, Arkansas, United States
🇺🇸Childrens Hospital Los Angeles ., Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.